Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases ...

Novartis reports that Fabhalta® achieved the Phase III APPLAUSE-IgAN primary endpoint, showing slowed kidney-function decline ...

I read your recent column where you said that ivermectin has not been proven to be an effective treatment for cancer. I feel ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 inhibitor (SGLT2-i) slows nodule growth and reduces the need for surgical ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

A type 2 diabetes medication may lower the risk of autoimmune rheumatic diseases like rheumatoid arthritis by 11%, unlike ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

CHEST 2025, the 90th annual meeting of the American College of Chest Physicians, opens on "Love Your Lungs Day" on October 19 in Chicago.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...